http://www.bicycletherapeutics.com
Bicycle Therapeutics plc Company Intro
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Industry
Healthcare
Bicycle Therapeutics plc Headquaters
Babraham Research Campus
Cambridge,CB22 3AT
United Kingdom
Bicycle Therapeutics plc Share price
17 May 2023 12:51 GMT
$23.50
-0.37 (-1.55 %)
Bicycle Therapeutics plc Market cap
$718.04 M
WMC RANKING
2024
Bicycle Therapeutics plc # 191
BiotechnologyLatest Bicycle Therapeutics plc News
09 Feb 2024
How Will the Market React to Bicycle Therapeutics PLC (BCYC) Stock Getting a Neutral Rating
The market has been neutral on Bicycle Therapeutics PLC (BCYC) stock recently. BCYC gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.
09 Feb 2024
How Will the Market React to Bicycle Therapeutics PLC (BCYC) Stock Getting a Neutral Rating
The market has been neutral on Bicycle Therapeutics PLC (BCYC) stock recently. BCYC gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.
09 Feb 2024
How Will the Market React to Bicycle Therapeutics PLC (BCYC) Stock Getting a Neutral Rating
The market has been neutral on Bicycle Therapeutics PLC (BCYC) stock recently. BCYC gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.
WMC Market Score
WMC Market to Revenue Score
Bicycle Therapeutics plc Market Financials
Revenue, Expenses, Profit
Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
Bicycle Therapeutics plc | USD | $11,069 | $67,410 | $-55,877 | $7,180M | 191 |
Regeneron Pharmaceuticals, Inc. | USD | $9,197,600 | $3,997,800 | $4,003,800 | $804,390B | 1 |
Vertex Pharmaceuticals Incorporated | USD | $6,414,881 | $2,617,257 | $2,762,032 | $878,880B | 2 |
Alexion Pharmaceuticals, Inc. | USD | $6,261,601 | $2,747,200 | $681,800 | $ 0.00 | 3 |
ALK-Abello A/S | USD | $3,556,000 | $1,893,000 | $66,000 | $189,400B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total Bicycle Therapeutics plc Social Followers vs Top 4 Industry Competitors
Bicycle Therapeutics plc Post vs Top 4 Industry Competitors
Bicycle Therapeutics plc Digital Footprint By Size vs Top 4 Industry Competitors
Bicycle Therapeutics plc Digital Footprint By Change Rate vs Top 4 Industry Competitors
Bicycle Therapeutics plc WMC Market Score Calculations
Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
Bicycle Therapeutics plc | 0.12 | 0 | 0 | 0 | 0 | 0 | 0 |
Regeneron Pharmaceuticals, Inc. | 100 | 25.50 | 16.15 | 70 | 0 | 0 | 39.85 |
Vertex Pharmaceuticals Incorporated | 69.75 | 35.68 | 8.95 | 100 | 0 | 0 | 51.56 |
Alexion Pharmaceuticals, Inc. | 68.08 | 100 | 100 | 80 | 0 | 0 | 100 |
ALK-Abello A/S | 38.66 | 0 | 0 | 0 | 0 | 0 | 0 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge